
News|Articles|September 1, 2005
FDA actions in brief
Valsartan (Diovan, Novartis) received an expanded indication for reducing cardiovascular mortality in patients who are at high risk due to left ventricular failure or dysfunction after myocardial infarction.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Rural health is ailing. Is $50 billion enough to heal it?
2
GLP-1 medications are linked to hair loss in Type 2 diabetes
3
Recombinant shingles vaccine linked to lower cardiovascular disease risk
4
Real-World Safety Experience and Clinical Takeaways from the BE BOLD Trial
5























